Beginning of prescription competition between Tresiba and Toujeo

The active competition among next-generation insulin has begun.

According to the industry concerned on the 28^th, after Novo Nordisk registered the health insurance benefit of ‘Tresiba(insulin degludec),’ a basal insulin, ‘Toujeo, ’a Sanofi-Aventis’s gene recombination product of ‘Lantus(insulin glargine),’ entered the circle of the health insurance benefit.

When it comes to the ceiling price ...